血红蛋白病
地中海贫血
遗传学
突变
生物
终止密码子
珠蛋白
基因
分子生物学
溶血性贫血
免疫学
作者
Qiong Su,Shiping Chen,Liu-Song Wu,Runmei Tian,Xiaoqin Yang,Xiaoyan Huang,Yan Chen,Zhiyu Peng,Jindong Chen
出处
期刊:Hemoglobin
[Informa]
日期:2019-01-02
卷期号:43 (1): 7-11
被引量:9
标识
DOI:10.1080/03630269.2019.1582430
摘要
Hemoglobinopathies are caused by genetic defects on the globin genes. To date, more than 900 β-globin variants have been recorded worldwide. These gene alterations often cause either a decrease in β-globin synthesis or completely block synthesis, leading to a hemoglobinopathy. While most of these causative mutations are inherited, de novo mutations are quite rare. Here, we investigated three hemoglobinopathy cases. These patients developed severe hemolytic anemia at 3-5 months of age and were transfusion-dependent. In patient 1, a novel β variant, Hb Zunyi [β147(HC3)Stop→Gln; HBB: c.442T>C] was identified. This de novo mutation results in a stop codon substitution to a glutamine residue at codon 147 of the β-globin gene, and leads to severe thalassemia. In patient 2, we discovered the rare Hb Southampton mutation [β106(G8)Leu→Pro; HBB: c.320T>C], while in patient 3, the rare Hb Alesha mutation [β67(E11)Val→Met (GTG>ATG); HBB: c.202G>A] was detected. The identification of the novel β variant, Hb Zunyi, has added to the human globin database and will shed light on future diagnosis of hemoglobinopathy/thalassemia and genetic counseling.
科研通智能强力驱动
Strongly Powered by AbleSci AI